Figure 3
Antitumour activity of PTX in combination with bevacizumab on 1A9-luc ovarian carcinoma xenograft. (A) Protocol of the study: treatments started 6 days after intraperitoneal 1A9-luc transplantation in nude mice and were given every 4 days. PTX (
) was used at the dose of 20 mg kg−1, i.v., Q4 × 3; Bev (
, 5 mg kg−1, i.p.) was interrupted after three cycles of chemotherapy or continued till death (
). (B and D) Mice were monitored by BLI on day 6 (randomisation) and days 17, 27, 39 (tumour progression) and the tumour burden was expressed as photon counts (n=10, #P<0.001 vs vehicle, **P<0.001 vs PTX and * P<0.01 vs PTX+Bev). (C and E) One representative mouse treated with vehicle, Bev, PTX, PTX+Bev or PTX+Bev→Bev imaged (C) on day 17 and (E) on day 39. (F) Effect of the different treatments on the lifespan of the mice (n=10; ***P<0.0001, **P=0.01, *P=0.02). Abbreviation: Bev=bevacizumab.
